Monoamine oxidase inhibitors and alprazolam in the treatment of panic disorder and agoraphobia.
This article reviews the evidence on the efficacy of monoamine oxidase inhibitors (MAOIs) and of alprazolam in the treatment of panic disorder and agoraphobia. It also presents guidelines to the clinician on how to implement these treatments in practice.
Sheehan
D V
DV
D000525:Alprazolam; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001569:Benzodiazepines / Q000008:administration & dosage / Q000627:therapeutic use*; D002611:Cheese / Q000009:adverse effects; D004032:Diet / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D005239:Fear / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007490:Iproniazid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010200:Panic / Q000187:drug effects*; D010624:Phenelzine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010698:Phobic Disorders / Q000188:drug therapy / Q000523:psychology; D014439:Tyramine / Q000009:adverse effects; D014920:Wine / Q000009:adverse effects
D014151:Anti-Anxiety Agents; D008996:Monoamine Oxidase Inhibitors; D001569:Benzodiazepines; D007490:Iproniazid; D010624:Phenelzine; D014439:Tyramine; D000525:Alprazolam